Franceschini, D., Greto, D., Dicuonzo, S., Navarria, F., Federico, M., La Vecchia, M., Sangalli, C., Allajbej, A., Di Cristina, L., Mazzola, R., Pontoriero, A., Montesi, G., Navarria, P., Baldaccini, D., Clerici, E., Lo Faro, L., Franzese, C., Di Biase, S., Pergolizzi, S., and Alongi, F.
• Oligometastatic sarcomas can be safely and effectively treated with SABR. • One out of 5 patients is free of progression at 2-years after SABR. • SABR can defer the need for systemic therapy with a median time of 19,5 months. Stereotactic Ablative Radiotherapy (SABR) is emerging as a valid alternative to surgery in the oligometastatic setting in soft tissue sarcomas (STS), although robust data are lacking. The aim of this study is to evaluate toxicity and efficacy of SABR in oligometastatic STS. This is a retrospective multicenter study including adult patients affected by stage IV STS, treated with SABR for a maximum of 5 cranial or extracranial metastases in up to 3 different organs. SABR was delivered with ablative purposes. Study endpoints were overall survival (OS), local control (LC), distant progression free survival (DPFS), time to polymetastatic progression (TTPP), time to new systemic therapy (TTNS) and toxicity. From 10 Italian RT centers, 138 patients (202 metastases) treated between 2010 and 2022 were enrolled in the study. Treatment was generally well tolerated, no acute or late toxicity ≥ G3 was recorded. Median follow up was 42.5 months. Median OS was 39.7 months. Actuarial OS at 1 and 2 years was 91.5 % and 72.7 %. Actuarial LC at 1 and 2 years was 94.8 % and 88.0 %. Median DPFS was 9.7 months. Actuarial DPFS at 1 and 2 years was 40.8 % and 19.4 %. SABR is a safe and effective approach for the treatment of oligometastatic sarcoma. One out of 5 patients is free of progression at 2-years. [ABSTRACT FROM AUTHOR]